您的位置:首页 > 产品中心 > Anti-p21WAF1 (Ab-1) Mouse mAb (EA10)
Anti-p21WAF1 (Ab-1) Mouse mAb (EA10)
产品别名
Anti-p21WAF1 (Ab-1) Mouse mAb (EA10)
Anti-CIP1, Anti-SD11, Anti-p21, Anti-WAF
产品性质
Quality Level【质量水平】 | 100 |
biological source【生物来源】 | mouse |
antibody form【抗体形式】 | purified antibody |
antibody product type | primary antibodies |
clone【克隆】 | EA10, monoclonal |
form【形式】 | liquid |
contains【包含】 | ≤0.1% sodium azide as preservative |
species reactivity | human |
should not react with | rat, mouse |
manufacturer/tradename | Calbiochem® |
storage condition【储存条件】 | do not freeze |
isotype【同位素/亚型】 | IgG1 |
shipped in【运输】 | wet ice |
storage temp.【储存温度】 | 2-8℃ |
packaging【包装】 | 20, 100 μg in Plastic ampoule Please refer to vial label for lot-specific concentration. |
基本信息
General description【一般描述】 | This Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) is validated for use in FC, Immunoblotting, IF, IP, Paraffin Sections for the detection of p21WAF1 (Ab-1). Recognizes the ~21 kDa p21WAF1 protein in skin and colon tissue and in cells expressing wild-type p53 (e.g. Hs27 or U205 cells treated with DNA damaging agents). |
Application【应用】 | Flow Cytometry (2 g/ml or use Cat. No. OP64F; see application references) Frozen Sections (5 g/ml or use Cat. No. OP64F) Immunoblotting (1-3 g/ml) Immunofluorescence (1-5 g/ml or use Cat. No. OP64F) Immunoprecipitation (2 g/sample) Paraffin Sections (5 g/ml or use OP64F; heat pre-treatment required; see comments and application references) |
Warning【警告】 | Toxicity: Standard Handling (A) |
Analysis Note【分析说明】 | Positive Control Any cell line expressing wild-type p53 (e.g. Hs27 or U2OS treated with DNA-damaging agents) or skin or colon tissue |
Other Notes【其他说明】 | Agarwal, M.L., et al. 1995. Proc. Natl. Acad. Sci. USA92, 8493. Chen, Y.Q., et al. 1995. Int. J. Oncology7, 889. Deng, C., et al. 1995. Cell82, 675. El-Deiry, W.S., et al. 1995. Cancer Res.55, 2910. Waldman, T., et al. 1995. Cancer Res.55, 5187. Elbendary, A., et al.1994. Cell Growth Diff.5, 1301. El-Deiry, W.S., et al. 1994 Cancer Res.54, 1169. Li, R., et al. 1994. Nature371, 534. Michieli, P., et al. 1994. Cancer Res.54, 3391. Noda, A., et al.1994. Exp. Cell Res.211, 90. El-Deiry, W.S., et al.1993. Cell75, 817. Gu, Y., et al. 1993. Nature366, 707. Harper, J.W., et al.1993. Cell75, 805. Xiong, Y., et al.1993. Genes Devel.7, 1572. Xiong, Y., et al.1993. Nature366, 701. Xiong, Y., et al.1992. Cell71, 505. Maximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS or MCF7 cells with DNA damaging agents (such as doxorubicin at 0.2 µg/ml) induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. Untreated cells will express little p21WAF1 and can be used as a negative control. Cat. No. OP64F was tested in HALT cells induced by incubation at 31°C; FITC-goat anti-mouse IgG (Cat. No. DC13L) was used as a negative control. This antibody will immunoprecipitate p21WAF1 but not associated proteins. For immunoblotting applications, use a 0.22 µm filter and visualize by chemiluminescence. For staining paraffin sections, heating the tissue in 10 mM citrate buffer is required (see application references). In either paraffin or frozen sections of normal human colon, the non-dividing cells of colonic epithelium will stain positive for p21WAF1 while the proliferating compartment of crypts will not stain. Antibody should be titrated for optimal results in individual systems. |
Legal Information【法律信息】 | CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany |
安全信息
Storage Class Code【储存分类代码】 | 11 - Combustible Solids |
WGK | WGK 1 |